Product Description
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PsiOxus
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bladder Cancer|Colorectal Cancer|Ovarian Cancer|Breast Cancer
Phase 1: Colorectal Cancer|Ovarian Cancer|Squamous Cell Carcinoma|Head and Neck Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03916510 |
CEDAR | P1 |
Completed |
Colorectal Cancer |
2023-02-24 |
50% |
2025-02-07 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments |
NCT02636036 |
SPICE | P1 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer|Colorectal Cancer |
2021-10-08 |
50% |
2023-01-06 |
Primary Endpoints|Treatments |
NCT02028117 |
OCTAVE | P1 |
Completed |
Ovarian Cancer |
2019-11-19 |
12% |
2023-01-06 |
Primary Endpoints|Treatments |
2016-004777-40 |
Long term follow up of subjects treated with enadenotucirev | P2 |
Completed |
Breast Cancer|Colorectal Cancer|Ovarian Cancer |
2020-09-07 |
2022-03-13 |
Treatments |
|
2013-001276-38 |
2013-001276-38 | P2 |
Completed |
Ovarian Cancer |
2020-01-08 |
2022-03-13 |
Treatments |
|
NCT02028442 |
EVOLVE | P2 |
Completed |
Bladder Cancer|Colorectal Cancer |
2016-04-29 |
2023-01-06 |
Primary Endpoints |